Skip to main content
Premium Trial:

Request an Annual Quote

Brazil Declines to Approve Sputnik V

Health regulators in Brazil have declined to approve Russia's Sputnik V vaccine for SARS-CoV-2, the Washington Post reports.

While Russia's quick approval of the vaccine last August, developed by researchers at the Gamaleya Institute, raised eyebrows as it had not finished phase III testing at the time, the researchers later reported in the Lancet that Sputnik V was safe and had 91.6 percent efficacy in preventing COVID-19.

But the Post reports that Brazilian regulators have raised concerns about the vaccine, namely about the lack of quality control and efficacy data as well as the limited information on side effects. "Flaws … were identified in all stages of clinical studies," Brazil's Health Regulatory Agency, or Anvisa, says in a statement, according to the Post. Anvisa adds that there weren't "any manufacturing conditions identified that demonstrate that the products are consistently produced and controlled."

According to the Post, the developers of the vaccine countered that the decision was political and has "nothing to do with access to information or science."

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.